A New Approach in Parkinson’s: Removing a Problem Protein
Silo: Voice of Health – Patient Edition
What’s Being Studied
Scientists are testing a new therapy called ARV-102. It helps cells identify and remove a protein called LRRK2 that may contribute to Parkinson’s. The first trial involved healthy adults to make sure it’s safe and to measure how the body responds.
Why It Matters
Unlike most drugs that block a single step in the disease process, this treatment encourages cells to clear the protein altogether. That could mean fewer side effects and a longer-lasting effect if it works safely.
Next Steps
If proven safe, future studies will test ARV-102 in people with Parkinson’s to see whether reducing LRRK2 can slow disease progression or improve symptoms.